Contact Us
ZENCORE BIOLOGICS · ONE-STOP BIOLOGICS CDMO

Explore, Honor, Perfect, Transcend Driven by science, dedicated to life

A one-stop biologics CDMO service platform from preclinical research to commercial manufacturing.

Guided by the values of “pursuing truth to serve humanity, striving for perfection,” Zencore Biologics is committed to delivering high-quality, high-efficiency CDMO services that empower partners to advance products rapidly from concept to commercial supply. By integrating best-in-class processes, we aim to make life-changing medicines accessible to all.

Explore Zencore Services
R&D Base Research & Discovery ADC Base Conjugate Manufacturing Pilot Base Scale-Up Production Commercial Base GMP Manufacturing US Innovation Center Global Innovation Hub 5 BASES
▶ Tour Zencore · 360° manufacturing base
25,000L
Total capacity
5
R&D and manufacturing bases
300+
Global clients
560+
Service projects
60
IND approvals
5
BLA filings
End-to-End Services

One-stop services covering the full lifecycle of drug development One-Stop CDMO Services

From early research to commercial manufacturing, Zencore Biologics can help clients rapidly and reliably advance candidate molecules to the clinic and market at every stage.

01

Research services

Research
  • Cell line construction and development
  • Early pharmaceutical research
  • Project feasibility evaluation
02

Development services

Development
  • Process development and scale-up
  • Analytical method development and validation
  • Pilot manufacturing (non-GMP/GMP)
03

Manufacturing services

Manufacturing
  • Drug substance (DS) manufacturing
  • Drug product (DP) filling
  • Global GMP supply
04

Quality & regulatory

Quality & Regulatory
  • Global CMC regulatory filings
  • Quality management and compliance
  • Regulatory strategy support
Our Capabilities

Service capabilities Core Service Platforms

Four core service segments building complete delivery capability from molecule to drug. Click a section to view detailed capabilities and manufacturing scale.

Biologics CDMO

Biologics CDMO

Integrated biologics CDMO services from developability assessment to commercial manufacturing.

01
Developability AssessmentCell Line DevelopmentUpstream and downstream processesFormulation DevelopmentClinical samplesCommercial manufacturing
15g/L
Maximum titer
3×2,000L
Single-use production lines
3×5,000L
Stainless-steel production lines
Explore Services

ADC CDMO

ADC CDMO

End-to-end conjugate drug development and manufacturing, from proof of concept to commercialization.

02
Site-specific conjugationToxin-linkerDrug substance manufacturingDrug product manufacturingQuality control
2000+
early stage projects
2
Independent DS production lines
5 m²/20 m²
Lyophilization lines
Explore Services

Cell culture media services

Cell Culture Media

Custom development on the Zncore® platform and GMP commercial manufacturing.

03
Custom formulationsPilot manufacturingZncore® catalogMedia testing
200 tonnes/year
Annual capacity
>5 g/L
Average titer
15 g/L
Maximum titer
Explore Services

Analytical services

Analytical CRO

Total solutions for biologics analysis and quality research, from sequence to BLA.

04
Release characterizationStabilityImpurity identificationSimilarity assessment
AUC
Analytical ultracentrifugation
Q-TOF/QE
High-resolution mass spectrometry
Sequence - BLA
Full-stage coverage
Explore Services
Why Zencore

Why choose Zencore Why Choose Zencore

Six reasons clients choose Zencore: platform depth, flexible and scalable capacity, cost leadership, neutrality, delivery speed and global competitiveness.

01

Strong integrated technology platforms

  • Mature process technology platforms with efficient tech transfer capability
  • Helped clients obtain 60 IND approvals and complete 5 BLA filings
02

Capacity that balances flexibility with scale

  • Both 2,000 L single-use and 5,000 L stainless-steel bioreactor capacity
  • Combines production scheduling flexibility with large-scale volume capability
  • Our 5,000 L stainless-steel facility was the first in China to pass PPQ
03

Superior cost control

  • High-titer, high-yield antibody process platforms lower manufacturing costs
  • Self-developed, locally sourced cell culture media cuts media costs by 50%
  • The scarce 5,000 L stainless-steel capacity further reduces unit cost
04

A pure, neutral CDMO model

  • No investment from any pharmaceutical sponsor
  • Maximum protection of client IP and data confidentiality
05

Rapid, dependable delivery

  • Preclinical process development for toripalimab completed in just 7 months (industry average: 12–18 months)
  • A 2,000 L BLA project reached first-scale production in only 10 months from kickoff, covering process optimization and media replacement
06

International competitiveness

  • Highly responsive, service-oriented engineering teams
  • More flexible capacity expansion with shorter build-out timelines
Milestones

Milestones Milestones

Key moments in Zencore's journey, from founding in Zhangjiang to commercial-scale GMP manufacturing.

Milestone in Financings

Jan. 2022, completed Series-C financing of $100 million.

Led by Goldman Sachs Asset Management and Sofina, with participation from Novo Holdings, Qiming Venture Partners, IDG Capital, LYFE Capital, GT Capital, and Cowin Capital.

Jan. 2022, 2021 China Venture ; VIGOROUS TOP 100. 

Milestone in Financings

Feb. 2021, completed Series-B financing of $70 million.

Led by Qiming Venture Partners and IDG Capital, with participation from CMB International, GP Capital, Cash Capital, and Hangzhou Fulin Investment Partnership.

Milestone in Financings

Jan. 2020, received Hansoh Pharma's Excellence in Cooperation Award.

Mar. 2020, completed Series-A financing of $ 55 million.

This round of financing was led by LYFE Capital, with participation from IDG Capital, Cowin Capital, Korea Investment Partners (KIP), GT Capital and Shanghai Growth-FOF.

Jun. 2020, received 2020 "Three Hundreds" Enterprise in Fengxian Award.

Oct. 2020, received Shanghai Federation of Industry and Commerce Membership Certificate.

Nov. 2020, received the Pharma BIG Star Rising Star of Chinese Biomedicine CDMO Enterprise in 2020.

Dec. 2020, became the Bioindustry List of Climbers.

Dec. 2020, selected as the 2020 Zero2IPO Venture50 and Top 50 Growing Companies & Top 50 Medical Companies. 

Company News

Dec. 2019, Certification of "High and New Technology Enterprise".

Jan. 2018, launched One-stop-shop CDMO Service in Zhangjiang Shanghai.

Nov. 2017, Zencore was founded.

News

News & updates News & Updates

All News →
Breaking News | Zencore Biologics Successfully Obtains the “Drug Production License,” Reaching an Important Milestone in Its Growth
2025-01-16

Breaking News | Zencore Biologics Successfully Obtains the “Drug Production License,” Reaching an Important Milestone in Its Growth

View details →
Congratulations | Novotel Biotech Approved to Conduct Phase I Clinical Trial of Recombinant Human Hyaluronidase Injection
2024-12-31

Congratulations | Novotel Biotech Approved to Conduct Phase I Clinical Trial of Recombinant Human Hyaluronidase Injection

View details →
Zencore's "Hyaluronidase" Pharmaceutical Excipient Registered with NMPA
2024-12-22

Zencore's "Hyaluronidase" Pharmaceutical Excipient Registered with NMPA

View details →
Congratulations to Zencore Biologics for being awarded the title of "Shanghai Key Service Unicorn Enterprise"
2024-04-28

Congratulations to Zencore Biologics for being awarded the title of "Shanghai Key Service Unicorn Enterprise"

View details →
Congratulations to D2M Biotherapeutics on the NMPA Approval for the First Proprietary Pipeline Product DM919
2024-04-12

Congratulations to D2M Biotherapeutics on the NMPA Approval for the First Proprietary Pipeline Product DM919

View details →
Strategic Collaboration | Zencore Biologics Signed a Strategic Cooperation Agreement with Apeloa Pharmaceutical
2024-03-06

Strategic Collaboration | Zencore Biologics Signed a Strategic Cooperation Agreement with Apeloa Pharmaceutical

View details →